Nanomaterials in Cancer: Focus on Molecular Targeting and Immunotherapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Nanoscience".
Deadline for manuscript submissions: 20 July 2024 | Viewed by 107
Special Issue Editor
Interests: cancer; biomaterials; nanotechnology; nanomedicine; theranostics; targeted nanomedicine; stimuli-responsiveness
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
There has been an intense research interest in the applications of nanomaterials in the diagnosis and therapeutics of cancers in the last decade, resulting in great advancements in the field of targeted-delivery nanomedicines. Nanoscience has focused on cancer therapy by exploiting the structural design of stimuli-responsive nanomaterials in combination with gene therapies, drug storage, and medical imaging using external stimuli such as radiotherapy, focused ultrasounds, photodynamic/photothermal chemotherapy, and hyperthermia to achieve improved effectiveness. Despite the great achievements of nanomaterials, solid tumors raise particularly important challenges, largely due to their complex and heterogenic microenvironment.
In the fight against solid tumors, newly developed nanomaterials have been designed to combat the challenges of heterogenic vasculature, dense stroma, extracellular matrix, hypoxia, and pH gradient acidosis. A crucial part of the imminent development of efficacious tumor therapies is played by molecular-targeting nanomaterials designed to interfere with tumor molecular abnormalities by delivering silencing RNA (siRNA) and micro RNA to sites for gene regulation. The ultimate goal of targeted molecular nanomaterials is the molecular reprogramming of host immune responses against tumor cells, tumor-associated macrophages (TAM), cancer-associated fibroblasts (CAFs), and cancer stem cells (CSCs). To this end, immunotherapies have received a lot of attention for regulating the host immune system’s natural defense mechanisms in order to inhibit primary, adaptive, and acquired resistance, and to deliver immunomodulatory therapeutics. The most recent example of a molecular therapy is that of CAR T cells against blood cancer.
I would like to invite you to submit research or reviews for this Special Issue with a focus on nanomaterials used for molecular targeting and immunotherapeutics.
Dr. Athina Angelopoulou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- nanomaterials
- molecular targeting
- immunotherapy
- gene therapy
- checkpoint inhibitors
- adoptive T-cell therapy
